¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11
±³À°ÀÏÀÚ : 2024-05-11
±³À°Àå¼Ò : ´õÄÉÀÌÈ£ÅÚ ¼­¿ï ±Ý°­È¦

±³À°ÁÖÁ¦ : The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium

ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ±è¹ÎÈñ
¿¬¶ôó : 010-8584-0193  

À̸ÞÀÏ : gaonpco@gaonpco.com

±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇÇб³À°

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 1Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ

¼¼ºÎ¼ö°­·á : 30,000¿ø  

ºñ°í »çÀüµî·Ï Àü¹®ÀÇ 2¸¸¿øÀü°øÀÇ 1¸¸¿ø ÇöÀåµî·ÏÀü¹®ÀÇ 3¸¸¿øÀü°øÀÇ 2¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 13:00~13:15 Locally advanced cancer (very high-risk or N1) in the PSMA era Á¶Á¤±â(ÇѾçÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 13:15~13:45 Panel discussion ±èÅûó(°í½ÅÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 13:45~14:00 Tactics of ADT administration - continous vs. intermittent ÀÌÇйÎ(¼­¿ïÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 14:00~14:30 Panel discussion ±èº´ÈÆ(°è¸íÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 14:50~15:05 Treatment choice following doublet/triplet therapy for mHSPC ¹ÚÁ¾¿í(¿øÀڷº´¿ø)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 15:05~15:35 Panel discussion Á¶¹®±â(¿øÀڷº´)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 15:35~15:50 The positioning of olaparib/abiraterone within mCRPC sequencing ÇÑÇöÈ£(¿¬¼¼ÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 15:50~16:20 Panel discussion Á¤Àç½Â(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 16:20~16:35 Apalutamide rash prevalence study: Updated results ±è¿øÅÂ(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 16:35~16:50 PSMA theranostics for prostate cancer ¼­¹Î¼®(¼­¿ïÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¸¸¼ºÆó¼â °ü»óµ¿¸Æ ÁßÀç½Ã¼ú¿¬±¸È¸ The 23rd K-CTO(Korean Chronic Total Occlusion Club) Live Demonstration : 2024-05-11
´ÙÀ½±Û 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-11
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21030 ¼­¿ï Á¦31ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (2ÀÏÂ÷) - ¿Â/¿ÀÇÁ º´Çà : 2024-06-28 0 11 2024-06-18
21029 ´ë±¸ 2024 ´ëÇÑÀÀ±ÞÀÇÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-28 0 14 2024-06-18
21028 ¼­¿ï 2024 ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-06-28 0 22 2024-06-18
21027 ºÎ»ê ´ëÇѽÉÀåÇÐȸ ±âÃÊ°úÇבּ¸È¸ ÇÏ°è½ÉÆ÷Áö¾ö 2024 : 2024-06-28 0 7 2024-06-18
21026 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾƳ»ºÐºñÇÐȸ ºñ¸¸¿¬±¸Áý´ãȸ 2024³â 1Â÷ : 2024-06-27 0 9 2024-06-18
21025 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°øÁߺ¸°ÇÀÇ»çÇùÀÇȸ 3Â÷ ¿Â¶óÀÎ ÇÏ°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-27 0 4 2024-06-18
21024 ºÎ»ê Á¦11Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Ãá°èÁ¾ÇÕ½ÉÆ÷Áö¾ö 1ÀÏÂ÷ : 2024-06-27 0 8 2024-06-18
21023 ´ë±¸ ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ ´ë±¸°æºÏÁöȸ 3Â÷ Áý´ãȸ : 2024-06-27 0 13 2024-06-18
21022 ¼­¿ï ´ëÇѼҾƸ¶ÃëÇÐȸ ¿Â¶óÀÎ 2024³â Èñ±Í³­Ä¡ Áúȯ ¸¶Ãë ÇÁ·ÎÅäÄÝ ¿þºñ³ª : 2024-06-27 0 14 2024-06-18
21021 ¼­¿ï (1ÀÏÂ÷)2024³â ´ëÇÑô¼öÇÐȸ 2nd ISCoS Regional Symposium : 2024-06-27 0 12 2024-06-18
21020 °­¿ø 2024 ö¿ø±ºÀÇ»çȸ 2Â÷ ¿¬¼ö°­ÁÂ_ÃÖ±Ù ÀÇÇÐÁö°ß(Ä¡¸Å, ¹é³»Àå°ú ³ë¾È) 0 8 2024-06-18
21019 ¼­¿ï Á¦31ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (1ÀÏÂ÷) - ¿Â/¿ÀÇÁ º´Çà : 2024-06-27 0 7 2024-06-18
21018 ÀüºÏ ±º»ê½ÃÀÇ»çȸ ¿¬¼ö±³À°(±â´É¼º ¼ÒÈ­ºÒ·®Áõ, º¸Çè½É»çÀÇ ÃֽŠÀ̽´) : 2024-06-27 0 14 2024-06-18
21017 ´ë±¸ 2024 ´ëÇÑÀÀ±ÞÀÇÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-06-27 0 11 2024-06-18
21016 ºÎ»ê 2024 ±ÝÁ¤±¸ÀÇ»çȸ Çмú´ëȸ(¿¹¹æÁ¢Á¾, ÇʼöÀÇ·áÆÐÅ°Áö) : 2024-06-27 0 10 2024-06-18
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷